Stockholm: The Health Emergency Preparedness and Response Authority has earmarked one point two billion euros for the next phase of its Medical Countermeasures Joint Procurement and Stockpiling Programme, with the bulk of expenditure focused on antiviral therapeutics, pandemic-relevant vaccines and broad-spectrum antimicrobials. The funding decision, ratified by the HERA Board last week, draws on the unspent residuals of the original 2022-2027 budget envelope.
HERA was established as a Commission service in 2021 in the wake of the COVID-19 response review. Its mandate is to anticipate, prevent and respond to cross-border health threats by ensuring development, manufacturing and equitable access to medical countermeasures. The Authority works closely with the European Medicines Agency, the European Centre for Disease Prevention and Control, and the Health Security Committee, all of which contribute to the threat assessment cycle.
Three programme areas receive the largest allocations. Antiviral therapeutics command the single largest single-year commitment, with three hundred million euros earmarked for joint procurement of orally administered agents effective against influenza A, respiratory syncytial virus and avian influenza variants of concern. The procurement is intended to underwrite manufacturing capacity rather than build a physical stockpile, an approach the Authority has refined since the early supply-chain experiences of the pandemic. A further two hundred and fifty million euros are reserved for next-generation broad-spectrum antibiotics under the antimicrobial resistance subprogramme, an area where market failure has long been documented. The third tranche, one hundred and seventy million euros, supports a renewed pandemic vaccine development partnership with Member State biomedical research institutes.
The funding model is itself a policy experiment. HERA pools national contributions and Commission funds in a single pot, then awards procurement and development contracts on a Union-wide basis. The European Centre for Disease Prevention and Control, based in this city, provides the epidemiological intelligence on which the Authority’s threat prioritisation depends. The two services have agreed an integrated threat assessment cycle that produces an annual list of pathogens of concern.
Several open questions remain. The first is governance. HERA operates as a Commission service rather than a fully independent agency, which has allowed for rapid scale-up but has also generated criticism from the European Parliament. A proposed legislative review, currently in inter-service consultation, would convert HERA into a decentralised agency with its own Management Board and legal personality. Whether this happens before the end of the current Commission mandate is uncertain.
The second is the interaction with national stockpiles. Several Member States maintain extensive medical countermeasure reserves that operate independently of the HERA framework. Negotiations on a coordinated stockpiling architecture have made progress but face national security objections in two capitals. A draft delegated act on stockpile interoperability is expected in the autumn.
The third is the scope of preparedness. HERA’s remit covers cross-border health threats broadly defined, including chemical, biological, radiological and nuclear incidents. The post-pandemic legislation expanded the Authority’s competence in this area, but implementing capacity has lagged. A pilot exercise with the Civil Protection Mechanism is under preparation for the autumn.
For the present, the funding commitment confirms that pandemic preparedness retains political backing despite competing budgetary pressures. The challenge is converting that backing into a stable, predictable architecture before memory of the last crisis fades entirely.
